JP2005518801A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005518801A5 JP2005518801A5 JP2003572502A JP2003572502A JP2005518801A5 JP 2005518801 A5 JP2005518801 A5 JP 2005518801A5 JP 2003572502 A JP2003572502 A JP 2003572502A JP 2003572502 A JP2003572502 A JP 2003572502A JP 2005518801 A5 JP2005518801 A5 JP 2005518801A5
- Authority
- JP
- Japan
- Prior art keywords
- component
- variant
- amino acid
- wild
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000023555 blood coagulation Effects 0.000 claims description 33
- 125000000539 amino acid group Chemical group 0.000 claims description 27
- 238000012986 modification Methods 0.000 claims description 21
- 230000004048 modification Effects 0.000 claims description 21
- 101800004937 Protein C Proteins 0.000 claims description 15
- 102000017975 Protein C Human genes 0.000 claims description 15
- 101800001700 Saposin-D Proteins 0.000 claims description 15
- 229960000856 protein c Drugs 0.000 claims description 15
- 230000035772 mutation Effects 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 102200080720 rs4077515 Human genes 0.000 claims description 10
- 230000014508 negative regulation of coagulation Effects 0.000 claims description 9
- 102220239971 rs1554273605 Human genes 0.000 claims description 9
- 102220014743 rs397517240 Human genes 0.000 claims description 9
- 102220291259 rs761208782 Human genes 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 102000012479 Serine Proteases Human genes 0.000 claims description 7
- 108010022999 Serine Proteases Proteins 0.000 claims description 7
- 102200014182 rs1555748926 Human genes 0.000 claims description 7
- 102220472978 Cytochrome c oxidase subunit 6B1_H10Q_mutation Human genes 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 238000012217 deletion Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- 230000003362 replicative effect Effects 0.000 claims description 3
- 102000004506 Blood Proteins Human genes 0.000 claims description 2
- 108010017384 Blood Proteins Proteins 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 8
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 108010000499 Thromboplastin Proteins 0.000 description 3
- 102000002262 Thromboplastin Human genes 0.000 description 3
- 206010056867 Activated protein C resistance Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 208000015294 blood coagulation disease Diseases 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 230000003024 amidolytic effect Effects 0.000 description 1
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36018102P | 2002-03-01 | 2002-03-01 | |
| US40104202P | 2002-08-06 | 2002-08-06 | |
| PCT/SE2003/000331 WO2003073980A2 (en) | 2002-03-01 | 2003-02-28 | Recombinant protein c variants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005518801A JP2005518801A (ja) | 2005-06-30 |
| JP2005518801A5 true JP2005518801A5 (enExample) | 2006-05-18 |
Family
ID=27791634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003572502A Pending JP2005518801A (ja) | 2002-03-01 | 2003-02-28 | 組換えプロテインｃバリアント |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050176083A1 (enExample) |
| EP (1) | EP1483380A2 (enExample) |
| JP (1) | JP2005518801A (enExample) |
| AU (1) | AU2003212739B2 (enExample) |
| CA (1) | CA2477876A1 (enExample) |
| WO (1) | WO2003073980A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008048646A1 (en) * | 2006-10-18 | 2008-04-24 | Socratech L.L.C. | Use of human protein c with altered glycosylation and sialic acid content as a medicament |
| EP2242875A4 (en) * | 2008-01-15 | 2012-04-04 | Univ British Columbia | PROTEIN-C-RS2069915 AS RESPONSE PREDICTOR FOR SURVIVAL RATE AND ADMINISTRATION OF AN ACTIVATED PROTEIN-C OR PROTEIN-C-SIMILAR COMPOUND |
| WO2012068519A2 (en) | 2010-11-19 | 2012-05-24 | Sirius Genomics Inc. | Markers associated with response to activated protein c administration, and uses thereof |
| WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9701228D0 (sv) * | 1997-04-03 | 1997-04-03 | Bjoern Dahlbaeck | Rekombinanta protein-C-och protein-S-varianter |
| US6017882A (en) * | 1997-10-23 | 2000-01-25 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| CA2391651A1 (en) * | 1999-11-19 | 2001-05-25 | Eli Lilly And Company | Protein c derivatives |
| EP1255821B1 (en) * | 2000-02-02 | 2004-12-29 | Eli Lilly And Company | Protein c derivatives |
-
2003
- 2003-02-28 AU AU2003212739A patent/AU2003212739B2/en not_active Ceased
- 2003-02-28 US US10/506,080 patent/US20050176083A1/en not_active Abandoned
- 2003-02-28 JP JP2003572502A patent/JP2005518801A/ja active Pending
- 2003-02-28 CA CA002477876A patent/CA2477876A1/en not_active Abandoned
- 2003-02-28 WO PCT/SE2003/000331 patent/WO2003073980A2/en not_active Ceased
- 2003-02-28 EP EP03708766A patent/EP1483380A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9982248B2 (en) | Factor IX polypeptide mutant, its uses and method for its production | |
| US10293043B2 (en) | Methods of lowering serum cholesterol | |
| JP6861152B2 (ja) | 治療用変異体アルファ２−マクログロブリン組成物 | |
| JP5427409B2 (ja) | 自己免疫疾患及び移植片拒絶反応を治療するためのＩｄｅＳプロテイナーゼ（化膿連鎖球菌由来）の使用 | |
| Liu et al. | Mesenchymal Stem Cells Promote the Osteogenesis in Collagen‐Induced Arthritic Mice through the Inhibition of TNF‐α | |
| TWI851647B (zh) | 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體 | |
| MXPA04010061A (es) | Factor viii modificado. | |
| TWI355419B (en) | Expression system and method for producing gamma-c | |
| US20060154331A1 (en) | Erythrocyte differentiation factor, gene encoding same, and methods of use thereof | |
| EP0914422B1 (en) | Mammalian genes involved in viral infection | |
| WO1998044128A1 (en) | Novel human serine carboxypeptidase | |
| JP2005518801A5 (enExample) | ||
| EP1860182B1 (en) | Method of regenerating elastic fiber with the use of dance or factor enhancing the expression thereof | |
| JP2021530524A (ja) | 発現が増強された組換えｆｖｉｉｉ変異体をコードするウイルスベクターを使用する血友病ａの遺伝子療法 | |
| WO1996016987A1 (en) | Thrombocytotic factor | |
| JP2008502323A (ja) | コブラ毒因子様機能を有するヒト補体ｃ３誘導体 | |
| EP1598367A1 (en) | Modified coagulation factors with enhanced stability and their derivatives | |
| US6835381B1 (en) | Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor | |
| EP1104771A1 (en) | NOVEL POLYPEPTIDE, cDNA ENCODING THE SAME AND UTILIZATION THEREOF | |
| TW459044B (en) | Protein MP-121 of the TGF-β-like family | |
| Holderbaum et al. | Arg519-Cys-associated haplotype in ice-landic family suggests early origin of this mutation | |
| CN119101140A (zh) | 一种促骨形成多肽及其应用 | |
| WO2022264040A1 (en) | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression | |
| EP1192181B1 (en) | Modulation of angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor for the treatment of tumor | |
| KR20250027325A (ko) | 병인성 비멘틴과 감염병 동반 악화 강직성척추염 질환 약물개발 모니터링 플랫폼 |